Informed Prostate Cancer Patient Support

Differential Radiobiological Effects of Αlpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival - International Journal of Radiation Oncology, Biology, Physics How to Make It Work at Lower Doses An IPCSG Newsletter feature on the radiobiology behind Pluvicto, Actinium-225, and the next wave of radioligand therapy. The author is a participant in a current Actinium 225 trial at UCSD Health Moores Cancer Center after having failed on Pluvicto. Bottom Line Up Front Targeted radionuclide therapy (TRT) — the class of treatment that includes the FDA-approved drug Pluvicto — delivers radiation directly to prostate cancer cells by riding on a molecule that locks onto PSMA , a protein studded on the surface of most prostate tumors. Two "payload" radioisotopes dominate the field: lutetium-177 (a beta-minus emitter, already approved) and actinium-225 (an alpha emitter, still investigational). A newly reported laboratory study from the German Cancer ...

The Clues Hidden in Failed Prostate Cancer Trials IPCSG Newsletter  •  Treatment Advances What the “Failures” Are Finally Teaching Us A patient-friendly review of the science — Summer 2026 BLUF (Bottom Line Up Front):    For fifteen years, the checkpoint-inhibitor drugs that revolutionized melanoma, lung, and kidney cancer failed one prostate-cancer trial after another — six large Phase 3 studies came back negative. But hidden inside those “failures” was a small group of men who had dramatic, lasting remissions. By studying those rare responders one cell at a time, researchers have now identified why most prostate tumors resist immunotherapy (immune-suppressing “SPP1” macrophages) and what lets a few tumors melt away (unusual killer T-cell populations). Today, only men whose tumors carry specific genetic signatures — mismatch-repair deficiency (dMMR), high microsatellite instability (MSI-H), or high tumor mutational burden (TMB) — have an FD...